Panorama News on October 13, 2020 Dayang Biotech (003017) initial public offering of shares and listing on the SME Board Online Roadshow was successfully held on the afternoon of October 13, 2020 (Tuesday) at Panorama Roadshow World.
Chen Yanggui, chairman and general manager of Dayang Biologics, Chen Xujun, financial director of Dayang Biologics, secretary of the board of directors and director of the Securities Department of Dayang Biologics, lu Deli, director of the equity financing department and sponsor representative of Caitong Securities, the sponsoring institution of Dayang Biologics, and the project manager of the equity financing department of Caitong Securities attended the event and conducted online interactive exchanges on issues that investors care about.
Chen Yanggui, chairman and general manager of Dayang Biologics, introduced in his speech that as a professional chemical raw material manufacturing enterprise, the company is mainly engaged in the production and sales of chemical raw materials such as inorganic salts and veterinary APIs, and has formed an industrial pattern of potash-based, veterinary drugs and fluorine-containing fine chemicals.
He said that since its establishment, the company adheres to green development and innovative development, continuously improves and optimizes the production technology process, improves the level of equipment technology, realizes the extension of the industrial chain and the comprehensive utilization of resources, and has become one of the important production enterprises of light potassium carbonate and ampaline hydrochloride in the world, and the production scale and product quality are in the leading position in the industry. Up to now, the company has 31 invention patents, 5 utility model patents, and has published more than 30 papers in core academic journals at home and abroad. The company has presided over the drafting of 5 national/industry standards, participated in the drafting of 1 national standard, has a more prominent industry status and research and development, technological innovation capabilities, leading the development direction of potassium carbonate and potassium bicarbonate industry.
The net amount of funds raised by Dayang Biotech in this offering is expected to be 382.6969 million yuan, and the investment funds are planned to be invested in the "project with an annual output of 25,000 tons of potassium carbonate and 15,000 tons of potassium bicarbonate", "the construction project of fluorinated fine chemicals" and the "supplementary working capital project".
In 2019, the company achieved operating income of 621.7507 million yuan, an increase of 6.44% year-on-year, and net profit of 79.4972 million yuan, an increase of 12.29% year-on-year. During the reporting period, the company continued to increase its market development efforts, market competitiveness and customer satisfaction continued to improve; the demand for downstream industries continued to increase, and sales continued to expand.
The highlights of the roadshow event are as follows:
What is the relevance and impact of the ampheline hydrochloride manufacturing industry and the downstream industry?
Xu Xuping, secretary of the board of directors and director of the Securities Department of Dayang Biologics: Ampheraline hydrochloride produced by the company belongs to the veterinary drug API and is widely used in animal husbandry and breeding. The livestock breeding industry and the veterinary drug industry are closely related and complement each other. Veterinary drugs as an upstream industry to provide a guarantee for the healthy development of animal husbandry, and animal husbandry as a downstream industry, its development scale, development model, development quality and breeding industry itself development law and profitability directly determine the demand for veterinary drugs, and then affect the development of the veterinary drug industry.
What is the company's pricing methodology and pricing principles?
Chen Xujun, financial director of Dayang Biotech: In terms of pricing methods and principles, the company adopts a cost-based and combined approach with market prices, that is, a certain proportion is added on the basis of cost, and at the same time, it is adjusted according to the market supply and demand situation and the negotiation with customers to determine the sales price of products. In the sales process, it is generally considered to give a part of the concession to the trader's customer, so the sales price of the trader's customer with the same specification product is generally lower than the sales price of the direct sales customer.
Please introduce the setting up of the company's R&D organization.
Xu Xuping, secretary of the board of directors of Dayang Biologics and director of the Securities Department: The company now has a postdoctoral workstation in Zhejiang Province, a provincial high-tech research and development center for ocean nanomaterials identified by the Zhejiang Provincial Science and Technology Department, a provincial enterprise technology center recognized by the Zhejiang Provincial Economic and Information Commission, and a potash research institute of Zhejiang Dayang Science and Technology identified by the Zhejiang Provincial Science and Technology Department, and has cooperated with Zhejiang University to build the Zhejiang Dahua Zhejiang University Biological Drug Research and Development Center, which has strong technical research and development strength. The company has built a R&D building of more than 4,000.00 square meters, equipped with multiple sets of pilot plants, advanced experimental instruments and equipment. The R&D center implements the director responsibility system in the operation and management, with 1 director and 1 deputy director, and 4 professional research groups and 1 testing center under the jurisdiction of inorganic chemical industry, fine chemical industry, drug research and development, biology and new materials. Each research group carries out research according to the company's development needs, and invites well-known experts in the industry to set up an academic committee to check the company's research and development direction and project selection.
Does the company have a new product development plan?
Xu Xuping, secretary of the board of directors and director of the Securities Department of Dayang Biologics: The company will continue to uphold the concept of "independent innovation and strong cooperation", continue to do a good job in the research and development of new products and technical reserves, and at the same time pay more attention to the technological upgrading of existing products and the extension of the industrial chain, laying the foundation for the sustainable development of the company. After years of development and accumulation, the company's production and market share of light potassium carbonate, potassium bicarbonate, ampheraline hydrochloride and 2-chloro-6-fluorobenzaldehyde are in the forefront of the world. In the future, the company will increase the development of new products on the basis of existing business areas, actively expand the product industry chain, and form a pattern of multi-variety industrial chain development in the fields of light potassium carbonate, ampaloline hydrochloride, fluorine-containing fine chemicals and new materials.
What is the relevance and impact of potassium carbonate and potassium bicarbonate manufacturing industry and downstream industry?
Xu Xuping, secretary of the board of directors and director of the securities department of Dayang Biologics: Potassium carbonate and potassium bicarbonate products are widely used in food, pesticides, medicine, fertilizers, glass and other industries. Food, pesticides, medicines, fertilizers and glass, as indispensable consumer goods in people's lives, are closely related to people's lives and have greater market demand. Changes in demand in downstream industries will directly affect the sales price of products in the industry.
This article originated from Panorama.com
![Potassium carbonate: intensive ecological development[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)